RHOVAC Image
IMAGE

RHOVAC

MARKET CAP - 238M SEK
MARKET CAP - 238M SEK

ABOUT US

RhoVac® is a pharmaceutical company dedicated to immuno-oncology, signifying that the body’s own immune system is stimulated to identify and destroy cancer cells. The primary focus of RhoVac® is to develop a cancer therapy that targets metastases to prevent cancer recurrence and progression after primary tumour therapy. 

Q&A WITH ANDERS MåNSSON  

Right arrow

What have been the milestones so far in your company development?

Awaiting.

Right arrow

What are your most important markets, segments and customers?

Awaiting.

Right arrow

Where do you see the company five years from now?

Awaiting.

Right arrow

What are your priorities within 2020/21?

Awaiting.

Right arrow

Why should one consider adding your company into their portfolio?

Awaiting.

PRODUCTS & SERVICES

RHOVAC Image
RHOVAC Image
RHOVAC Image

MEDIA